| Literature DB >> 35971375 |
Tejaswi Venigalla1, Christine Adekayode1, Shriya Doreswamy1, Hussein Al-Sudani1, Supriya Sekhar1.
Abstract
Babesiosis is an infectious disease that is typically known to present with fevers, chills, and myalgias; and less commonly with anorexia, headache, nausea, and vomiting. The least common are shortness of breath, sore throat, neck stiffness, emotional lability, photophobia, and dark urine. Even more unusual are severe neurologic manifestations like altered mental status, motor deficits, and ataxia. We present two cases of patients, both in their seventies, with multiple comorbidities, who were admitted with similar symptoms of confusion/cognitive impairment, slurred speech, ataxia, fever, myalgias and chills, urinary frequency, and urgency, with no previous history of travel outside the country or tick bites. Both patients had extensive workup, which raised suspicion of hemolytic infections, especially babesiosis and malaria. Considering our patients had not traveled out of the country, we leaned more toward babesiosis. The patients were treated appropriately for babesiosis and were also empirically treated for Lyme's, anaplasmosis, along with Mycoplasma in the second patient. Following two days of treatment, cognition, as well as speech, improved dramatically. On outpatient follow-up, both patients had entirely resolved hemolysis, parasitic load, and neurological manifestations. During the literature review, neurologic manifestations, being associated with babesiosis, were found to be exceedingly rare but could be fatal if left undiagnosed. It is an infection that is associated with complete recovery on prompt diagnosis and treatment. It is pertinent to have a high suspicion of this disease, especially in endemic areas, such as the Northeast United States, even more so when seen with hematologic and neurologic manifestations.Entities:
Keywords: altered mental status; babesiosis; hemolytic anemia; lyme's disease; malaria; neurological manifestations; parasites; stroke-like; tick bite; tick borne infections
Year: 2022 PMID: 35971375 PMCID: PMC9374020 DOI: 10.7759/cureus.26811
Source DB: PubMed Journal: Cureus ISSN: 2168-8184
Figure 1With arrows toward the intracellular ring-like parasites from the patient in Case #1
Labs of our first patient
ALT: alanine transaminase; AST: aspartate aminotransferase; LDH: lactate dehydrogenase
| CMP | On Presentation | On Follow-up | Reference Ranges |
| Sodium (mmol/L) | 132 | 139 | 134-144 |
| Creatinine (mg/dL) | 1.57 – unknown baseline | 1.06 | 0.7 – 1.2 |
| Total bilirubin (mg/dL) | 2.1 | 0.4 | 0.0-1.2 |
| Direct bilirubin (mg/dL) | 1.1 | NA | 0.1-0.5 |
| ALT (IU/L) | 127 | 32 | 0 – 55 |
| AST (IU/L) | 210 | 36 | 5 – 34 |
| CBC | |||
| Hemoglobin (gm/dL) | 12.7 | 10.4 | 11.1 – 15.9 |
| Hematocrit (%) | 37.3 | 32.9 | 34.0 – 46.6 |
| Red cell distribution width (RDW) (%) | 16.7 | 20.8 | 11.7-15.4 |
| Mean corpuscular volume (MCV) (fl) | 80.7 | 88 | 79-97 |
| Platelets (103mcL) | 43 | 343 | 150 – 450 |
| Reticulocyte count (%) | 2.3 | NA | 0.4-2.0 |
| Immature reticulocyte fraction (IRF) (%) | 16.7 | NA | 2.3-13.4 |
| Parasitic load on peripheral smear (%) | 1.8 | 0 | 0 |
| LDH (IU/L) | 752 | NA | 125 - 220 |
| Haptoglobin (mg/dL) | 8.0 | NA | 14 - 258 |
Figure 2With arrows toward the intracellular ring-like parasites from the patient in Case #2
Labs for our second patient
ALT: alanine transaminase; AST: aspartate aminotransferase; LDH: lactate dehydrogenase
| CMP | On Presentation | On Follow-up | Reference Ranges |
| Sodium (mmol/L) | 131 | 139 | 134-144 |
| Creatinine (mg/dL) | 1.06 | 0.65 | 0.7 – 1.2 |
| Total bilirubin (mg/dL) | 1.6 | NA | 0.0-1.2 |
| Direct bilirubin (mg/dL) | 0.8 | NA | 0.1-0.5 |
| ALT (IU/L) | 50 | 32 | 0 – 55 |
| AST (IU/L) | 63 | 36 | 5 – 34 |
| CBC | |||
| Hemoglobin (gm/dL) | 7.8 | 11.8 | 11.1 – 15.9 |
| Hematocrit (%) | 21.2 | 36.1 | 34.0 – 46.6 |
| Red cell distribution width (RDW) (%) | 15.1 | 15.2 | 11.7-15.4 |
| Mean corpuscular volume (MCV) (fl) | 82.5 | 99.4 | 79-97 |
| Platelets (103mcL) | 60 | 267 | 150 – 450 |
| Reticulocyte count (%) | 2.0 | NA | 0.4-2.0 |
| Immature reticulocyte fraction (IRF) (%) | 7.2 | NA | 2.3-13.4 |
| Parasitic load on peripheral smear (%) | 1.5 | 0 | 0 |
| LDH (IU/L) | 805 | NA | 125 - 220 |
| Haptoglobin (mg/dL) | 8.0 | NA | 14 - 258 |
Treatment of babesiosis
| Treatment | Preferred | Alternative |
| Babesiosis in Immunocompetent hospitalized patients | Atovaquone 750 mg orally every 12 hours plus azithromycin 500 mg intravenous (IV) every 24 hours until symptoms abate, then transition to atovaquone 750 mg orally every 12 hours plus azithromycin 250 to 500 mg orally every 24 hours to complete a 7 to 10-day course in total | Clindamycin 600 mg IV every 6 hours plus quinine sulfate 542 mg base (which equals 650 mg salt) orally every 6 to 8 hours, then transition all of them to oral dosing to complete a total course of 7 to 10 days. |
| Babesiosis in Immunocompromised patients | Atovaquone 750 mg orally every 12 hours plus azithromycin 500 mg IV every 24 hours, then transition to oral azithromycin as symptoms abate, but the dosage of oral azithromycin of 500 -1000 mg daily dose is recommended. The total duration of treatment is 6 consecutive weeks. | Alternative treatment is clindamycin 600 mg IV every 6 hours plus quinine sulfate 650 mg orally every 8 hours until symptoms abate, then convert all of them to oral therapy. This is also for a total duration of 6 consecutive weeks. |